30 June 2021 - Sanofi Aventis is strengthening its position in the local dyslipidaemia treatment market with Praluent (alirocumab), a treatment for patients with high-risk cardiovascular diseases, armed with high efficacy data for Koreans, the company said Wednesday.
The Ministry of Health and Welfare has granted reimbursement for Praluent, effective on June 7.
With the insurance benefits, patients with primary hypercholesterolaemia and mixed dyslipidaemia who have received statin and ezetimibe in combination with the insufficient response and statin intolerance can receive reimbursement.